| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED MAY 2018. Refer to TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | interferon beta-1a (Rebif®) | |
| Formulation | solution for injection | |
| Reference number | 1510 | |
| Indication | Treatment of patients with a single demyelinating event with an active inflammatory process |
|
| Company | Merck Serono Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 19/06/2012 | |
| Date of issue | 19/06/2012 | |
| NICE guidance | TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
|